WORLD EMERGENCY MEDICINE SOCIETIES & RELATED

Search

Content:

Thursday, September 29, 2022

TNK for AIS

SGEM#37 - By admin - September 24, 2022
Reference: Menon et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. The Lancet 2022
CLINICAL QUESTION: IS TENECTEPLASE NON-INFERIOR TO ALTEPLASE IN TREATING ACUTE ISCHEMIC STROKE?
KEY RESULT: TENECTEPLASE WAS NON-INFERIOR TO ALTEPLASE IN STROKE PATIENTS TREATED WITHIN 4.5 HOURS OF SYMPTOM ONSET
SGEM BOTTOM LINE: WE REMAIN SKEPTICAL ABOUT THROMBOLYSIS FOR ACUTE ISCHEMIC STROKE WHETHER IT IS DONE WITH ALTEPLASE OR TENECTEPLASE